BUYOUT OF TRIUS - LAW FIRM SEEKS HIGHER PRICE FOR SHAREHOLDERS
Tripp Levy PLLC, a leading national securities and shareholder rights law firmis investigating the Board of Directors of Trius Therapeutics, Inc. (“Trius” or the “Company”) (TSRX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Cubist Pharmaceuticals, Inc. (CBST).
Under the terms of the transaction, Trius shareholders will receive $13.50 in cash for each share of Trius stock they own. Trius shareholders will also be eligible to receive one Contingent Value Right of up to $2.00 per share should certain commercial milestones be met. The investigation concerns whether the Trius Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the transaction, and whether Cubist Pharmaceuticals, Inc. is underpaying for Trius, thus unlawfully harming Trius shareholders. In particular, at least one analyst set a price target for Trius stock at $20.00 per share.
If you own common stock in Trius and wish to obtain additional information, please contact us at 1-877-772-3975 or email at contact @ tripplevy